Regenerative orthopedics focuses on stimulating and enhancing our body's natural ability to respond to orthopedic injuries and heal itself. Often, this process is incomplete or delayed due to age, the chronicity of an injury, metabolic dysfunction, chronic illness, or medication.
Regenerative orthopedics applies advanced orthobiologic techniques, each with the potential to stimulate the immune system and increase the body’s natural ability to heal damaged tissues such as muscles, tendons, ligaments, bones, and cartilage.
Platelet Poor Plasma (PPP) is an autologous blood-derived fraction generated during the centrifugal separation of Platelet-Rich Plasma (PRP). While PPP contains a lower concentration of platelets compared to whole blood, it is rich in biological factors, most notably high levels of fibrinogen and essential plasma proteins. During the tissue repair process, fibrinogen converts into a dense fibrin network that forms a structural clot. This matrix enables platelets to gradually release over 300 bioactive signaling proteins, including key growth factors and cytokines that initiate and direct the body's natural inflammatory and healing cascades.
Clinically, PPP can be applied independently or combined with other orthobiologic formulations. It is particularly valuable for creating autologous thrombin and custom fibrin scaffolds. Recent scientific literature supports its specific utility in sports medicine and regenerative orthopedics for muscle tissue recovery. Studies show that PPP directly stimulates myoblast proliferation—the essential precursor cells required for muscle fiber repair, regeneration, and functional recovery following acute strain or chronic degenerative injuries.
Autologous Thrombin serves as the critical enzymatic catalyst in the physiological blood coagulation cascade, responsible for converting soluble plasma fibrinogen into a solid, cross-linked fibrin matrix. When isolated from the patient’s own blood and combined with Platelet-Rich Plasma (PRP) or bone marrow products, autologous thrombin immediately transforms liquid biologic concentrates into a flexible, bioactive gel or fibrin clot at the point of care.
From a clinical delivery perspective, this gelation is essential. The resulting fibrin scaffold physically secures platelets, stem cells, and growth factors at the precise target site, preventing fluid runoff and localized wash-out into surrounding tissues. Furthermore, this fibrin network acts as a temporary biological scaffold that supports cell migration, structural remodeling, and sustained protein release over time. Autologous thrombin enhances structural retention during minimally invasive procedures, offering a safer, fully biocompatible alternative to bovine-derived thrombin and optimizing outcomes in complex tendon, cartilage, and bone defect repairs.
Autologous Conditioned Serum (ACS) is an advanced orthobiologic therapy engineered to target and neutralize Interleukin-1 (IL-1), one of the primary inflammatory cytokines responsible for joint degeneration, pain, and cartilage breakdown. Produced by incubating the patient's own peripheral blood with specialized medical-grade beads, ACS stimulates the overproduction of Interleukin-1 Receptor Antagonist (IL-1RA) alongside complementary anti-inflammatory cytokines and growth factors.
Widely utilized in Europe and internationally under clinical protocols such as Orthokine and Regenokine, ACS provides a natural, physiologically balanced alternative to synthetic corticosteroid injections. By competitively binding to IL-1 receptors on target tissues, IL-1RA effectively blocks the inflammatory signals that accelerate structural joint breakdown. This therapy is highly indicated for patients suffering from mild-to-moderate osteoarthritis, chronic tendinopathies, ligament inflammation, radicular back pain, and joint stiffness. It offers durable symptomatic relief, improved joint mobility, and protective anti-inflammatory benefits without the cellular toxicity or tissue weakening risks associated with repeated steroid use.
Alpha-2-Macroglobulin (A2M) is a powerful, naturally occurring plasma glycoprotein synthesized primarily in the liver and locally by connective tissue cells. Functions as a broad-spectrum master protease inhibitor, A2M plays a vital role in joint preservation by capturing and inactivating destructive catabolic enzymes—such as matrix metalloproteinases (MMPs) and aggrecanases—that actively decompose articular cartilage and joint structures.
To achieve therapeutic efficacy, high concentrations of A2M are isolated from the patient’s blood through advanced processing of platelet-poor plasma. When injected directly into an injured or degenerative joint capsule, concentrated A2M binds to harmful enzymes, preventing them from degrading the collagen scaffold of the articular cartilage. This action halts progressive joint destruction, reduces localized intra-articular inflammation, and restores a favorable environment for biological tissue repair. A2M therapy is particularly suited for individuals with post-traumatic joint injuries, early-to-moderate osteoarthritis, or chronic joint instability seeking to preserve native cartilage integrity.
Bone Marrow Concentrate (BMC) is a potent autologous orthobiologic treatment that harnesses the body's primary reservoir of regenerative cells and anti-inflammatory signaling molecules. Extracted safely from the patient's posterior iliac crest under local anesthesia, the raw bone marrow aspirate undergoes precise density-gradient centrifugation to isolate a concentrated blend of mesenchymal stem/stromal cells (MSCs), hematopoietic progenitor cells, platelets, and bioactive proteins.
A unique advantage of BMC is its elevated concentration of natural anti-inflammatory agents, including Interleukin-1 Receptor Antagonist (IL-1RA), paired with a cellular framework that promotes vascular and tissue regeneration. When reinjected into damaged soft tissues, joints, or bone under direct ultrasound or fluoroscopic guidance, BMC helps coordinate cell differentiation, downregulates chronic inflammation, and stimulates structural tissue synthesis beyond what blood-derived PRP alone can achieve. BMC is frequently recommended for moderate-to-severe joint osteoarthritis, non-healing tendon tears, focal cartilage defects, subchondral bone lesions, and delayed-union fractures.
Progenitor Cell Therapy utilizes adult multipotent signaling cells—harvested primarily from autologous bone marrow or adipose tissue—that possess the biological capability to self-replicate and differentiate into specialized musculoskeletal cell lines, including chondrocytes (cartilage), osteoblasts (bone), and tenocytes (tendon). When deployed alongside Platelet-Rich Plasma (PRP), which delivers a supportive matrix of growth factors, progenitor cell therapy provides a comprehensive biological signal to revive tissues with limited native vascularity or extensive structural damage.
Adipose-Derived Progenitor Cell Therapy utilizes autologous fat tissue as an exceptionally rich source of medicinal signaling cells (MSCs), pericytes, pre-adipocytes, endothelial cells, and extracellular matrix components. Extracted through a gentle, minimally invasive lipoaspiration procedure, adipose tissue yields a higher volume of viable multipotent cells per unit volume than many other adult tissue sources, making it a powerful medium for regenerative orthopedics.
Beyond its cellular density, adipose tissue functions as an ideal structural bio-scaffold. When processed into a micro-fragmented tissue graft, it provides physical stability, soft tissue cushioning, and structural support within structural defects in tendons, ligaments, and cartilage. Simultaneously, these cells secrete paracrine signaling factors and immunomodulatory cytokines that reduce chronic intra-articular inflammation and promote local vascularization. This combination of mechanical scaffolding and localized biochemical signaling makes adipose-derived therapy an excellent intervention for advanced joint osteoarthritis, recalcitrant tendinopathies, and complex soft tissue defects requiring long-term biological support.
Amniotic tissue allografts utilize non-embryonic biological materials derived from human placental tissue and amniotic fluid, voluntary donated following planned, full-term Cesarean deliveries. These donated tissues undergo stringent screening and processing to create sterile allografts rich in extracellular matrix proteins, hyaluronic acid, immunomodulatory cytokines, and crucial growth factors (such as TGF-beta and PDGF) that support tissue preservation and reduce localized inflammation.
While preserved amniotic fluid formulations do not contain viable, live stem cells after processing, they provide a bioactive signaling environment that stimulates the patient's native surrounding cells to initiate structural repair. Amniotic tissue allografts serve as a valuable alternative for patients who are not optimal candidates for autologous cell harvesting due to advanced age, underlying systemic conditions, autoimmune disease, recent malignancy, or recent exposure to chemotherapy or radiation therapies. Common applications include managing arthritic joint pain, chronic bursitis, soft tissue inflammation, and complex tendinopathies.
Viscosupplementation is an established non-surgical treatment designed to alleviate symptoms of osteoarthritis by restoring the physiological properties of synovial fluid within affected joints. In healthy joints, naturally occurring Hyaluronic Acid (HA) serves as a primary lubricant and shock absorber, enabling frictionless articulation and protecting joint cartilage. In osteoarthritic joints, the concentration and molecular weight of natural HA are significantly reduced, resulting in increased joint friction, stiffness, pain, and secondary inflammation.
The procedure involves injecting medical-grade, highly purified hyaluronic acid directly into the intra-articular space under ultrasound guidance to ensure precise placement. Viscosupplementation restores fluid elasticity and lubrication, reduces mechanical joint grinding, improves overall range of motion, and helps suppress inflammatory pathways within the synovium. While most widely utilized and insurance-covered for knee osteoarthritis, viscosupplementation is also used clinically off-label to provide pain relief and functional improvement in other synovial joints, including the hip, shoulder, and ankle.
Corticosteroid injections have long served as a foundational intervention for rapidly suppressing severe pain and acute musculoskeletal inflammation. Typically formulated by combining a synthetic glucocorticoid with a local anesthetic (such as lidocaine), these injections work by downregulating local inflammatory pathways, reducing joint effusion, and providing prompt symptomatic relief directly within affected joints, bursae, or tendon sheaths.
While corticosteroid injections offer predictable, rapid short-term relief during acute pain flare-ups, their long-term use is carefully regulated due to potential adverse effects on tissue integrity. Repeated steroid exposure can lead to cartilage matrix breakdown, tendon weakening or rupture, local tissue atrophy, osteonecrosis, and transient blood glucose spikes in diabetic patients. Consequently, guidelines limit the total number of injections a patient may receive in a single site per year. Corticosteroids are best utilized as a targeted short-term bridge to decrease severe pain, allowing patients to participate comfortably in physical therapy or transition toward regenerative treatments.
Regenerative orthopedics is a branch of medicine focused on stimulating and enhancing your body’s natural ability to heal itself after an orthopedic injury. By applying advanced orthobiologic techniques, these treatments help revive delayed or incomplete healing responses in damaged muscles, tendons, ligaments, bone, and cartilage.
Regenerative Orthopedic therapies use orthobiologic and cell-based treatments for a wide range of clinical applications in a variety of different orthopedic and musculoskeletal abnormalities. Several of the most conditions that might benefit from orthobiologic or cell-based injections include:
It is normal to experience mild to moderate discomfort at and surrounding the treatment site for several days. Discomfort will vary depending on the specific Orthobiologic formulation used and body part treated. Soft tissue treatments such as tendons, tend to result in a slightly greater discomfort, swelling and stiffness for a short period of time. Application of moist heat 4 times per day post treatment will significantly reduce discomfort and swelling, facilitate blood flow, improving potential for healing. Over the counter acetaminophen (Tylenol) or prescribed analgesic medications can also be used to reduce more severe discomfort on an as needed basis. You will be instructed on how to safely move the treatment area while at home to prevent stiffness and maintain joint mobility. Strenuous activity is restricted for the first 3-4 weeks after treatment. A treatment specific physical therapy program will be prescribed to begin 2 to 3 weeks after treatment in most individuals.
Expected results will depend on several factors, the severity of your injury, the length of time it has been present and finally the treatment that was performed. In most cases, results will be noticed within 3 to 4 weeks in most joint procedures and from 6 to 10 weeks after soft tissue procedures. The majority of cases can be treated with a single treatment. However, every individual heals differently and occasionally a second treatment, or a booster treatment will be indicated for persistent or reoccurrence of symptoms.
Unfortunately, orthobiologic procedures are still considered investigational by insurance carriers and therefore are not reimbursed despite the ever-growing interest and evidence in the medical literature worldwide. This cannot be billed to your insurance carrier and a cash payment will be required prior to or at the time of the procedure.
If you have arthritis, low back pain, muscle, ligament or a tendon injury, or if you are just not improving with conservative measures and want to avoid surgery as long as possible, a regenerative orthopedic treatment may be for you.
If you have been diagnosed with active cancer or infection or have been diagnosed with lymphoma or other forms of chronic disease you may not be eligible unless cleared by your personal physician.
With recognized expertise in advanced shockwave technology, we deliver targeted acoustic pressure waves to injured tissue to reduce pain, break down chronic scar tissue, and stimulate the body's natural healing response in muscles, tendons, ligaments, and joints.
Regenerative orthopedics focuses on stimulating and enhancing our body's natural ability to respond to orthopedic injuries and heal itself. It applies advanced orthobiologic techniques, each with the potential to stimulate the immune system and increase the body’s natural ability to heal.
With recognized expertise in developing tailored rehabilitation strategies to safely transition injured athletes back to the field, we focus on fully restoring functional movement, optimizing recovery, and returning athletes to peak performance.
When an injury keeps you offstage, choosing the right physician is essential. Performance-related injuries affect drummers, concert pianists, and young dancers alike, making it critical to select a doctor who deeply understands the unique physical demands of your craft to ensure a safe, precise, and swift return to peak performance.
Appointments in Naples, FL, and monthly in Los Angeles, CA. Space in the practice is intentionally limited.
Patient Resources
